Jeff Yufeng Yang (Jeff Y Yang)

Years Active: 2019-2022
Publications (10 Years): 5

Acumen LLC

University of North Carolina at Chapel Hill Gillings School of Global Public Health (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Acumen LLC

United States

Policy Lead :: Safe Rx

Education History

University of North Carolina at Chapel Hill Gillings School of Global Public Health

United States

PHD :: Department of Epidemiology

Columbia University Department of Biomedical Engineering

United States

BSC :: Department of Biomedical Engineering

Publications

Jeff Yufeng Yang, Jennifer L Lund, Virginia Pate, Michael D Kappelman
Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019. Inflammatory bowel diseases (2022)
Shahar Shmuel, Jeff Yufeng Yang, Sydney Thai, Michael Webster-Clark, Jennifer L Lund
Assessing clinical trial effects on outcomes among pediatric and adolescent and young adult (AYA) patients with cancer. Cancer 127 (4) (2020)
Jeff Yufeng Yang, Tiansheng Wang, Virginia Pate, John B Buse, Til Stürmer
Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier's gangrene. BMJ open diabetes research & care 8 (1) (2020)
Stephanie B Wheeler, Meghan C O'Leary, Jewels Rhode, Jeff Yufeng Yang, Rebecca Drechsel, Marcus Plescia, Daniel S Reuland, Alison T Brenner
Comparative cost-effectiveness of mailed fecal immunochemical testing (FIT)-based interventions for increasing colorectal cancer screening in the Medicaid population. Cancer 126 (18) (2020)
Jeff Yufeng Yang, Tiansheng Wang, Virginia Pate, Emily W Gower, Matthew J Crowley, John B Buse, Til Stürmer
Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers. Diabetes, obesity & metabolism 21 (5) (2019)

Jeff Yufeng Yang.css-eqlu8i{font-size:small;padding-left:4px;} (Jeff Y Yang)